menu
    • menu

    Company profile for Levicept

    NEW Drugs in Dev: 1
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Levicept is a biotechnology company based in the UK that is focused on the development of a novel biological therapy called LEVI-04 (p75NTR-Fc) for the treatment of chronic pain. LEVI-04 is currently undergoing a phase II clinical trial in patients with osteoarthritis of the knee. The therapy works by modulating the neurotrophin pathway, which has been clinically proven to offer effective pain relief in various indications. Im...
    Levicept is a biotechnology company based in the UK that is focused on the development of a novel biological therapy called LEVI-04 (p75NTR-Fc) for the treatment of chronic pain. LEVI-04 is currently undergoing a phase II clinical trial in patients with osteoarthritis of the knee. The therapy works by modulating the neurotrophin pathway, which has been clinically proven to offer effective pain relief in various indications. Importantly, LEVI-04 is designed to minimize the use-limiting side effects associated with anti-NGF antibodies, including the risk of rapid osteoarthritis progression.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Leviceptunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    Ramsgate Road Sandwich Kent CT13 9ND
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.levicept.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/levicept-ltd/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Levicept Names James Sandy Chief Development Officer
    Levicept Names James Sandy Chief Development Officer

    04 Feb 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-02-04/levicept-announces-the-appointment-of-james-sandy-as-chief-development-officer-1

    PHARMIWEB
    04 Feb 2026
    Share Share
    Levicept's IND For LEVI-04, Osteoarthritis Treatment, Accepted
    Levicept's IND For LEVI-04, Osteoarthritis Treatment, Accepted

    20 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-20/levicept-announces-fda-acceptance-of-ind-application-for-levi-04-a-potentially-disease-modifying-treatment-for-osteoarthritis

    PHARMIWEB
    20 Jan 2026
    Share Share
    Levicept Data Shows LEVI-04 May Modify Disease in Osteoarthritis
    Levicept Data Shows LEVI-04 May Modify Disease in Osteoarthritis

    27 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/27/3174350/0/en/Levicept-Presents-New-Data-Suggesting-a-Novel-Neurotrophin-3-Inhibitor-LEVI-04-May-Modify-Disease-and-Improve-Symptoms-in-Osteoarthritis.html

    GLOBENEWSWIRE
    27 Oct 2025
    Share Share
    Levicept To Unveil Phase Ii Levi-04 Neurotrophin-3 Inhibitor
    Levicept To Unveil Phase Ii Levi-04 Neurotrophin-3 Inhibitor

    25 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/25/3156017/0/en/Levicept-to-Present-Key-New-Data-from-Phase-II-Trial-of-LEVI-04-a-Novel-Neurotrophin-3-Inhibitor-at-ACR-Convergence-2025.html

    GLOBENEWSWIRE
    25 Sep 2025
    Share Share
    Levicept to Present Phase II Trial Analysis, LEVI-04, at EULAR
    Levicept to Present Phase II Trial Analysis, LEVI-04, at EULAR

    12 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/12/3098073/0/en/Levicept-to-Present-Further-Analysis-from-Phase-II-Trial-of-Novel-Neurotrophin-3-Inhibitor-LEVI-04-at-EULAR.html

    GLOBENEWSWIRE
    12 Jun 2025
    Share Share
    Levicept Presents Positive Phase II Data for LEVI-04
    Levicept Presents Positive Phase II Data for LEVI-04

    26 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/26/3068691/0/en/Levicept-Presents-Positive-Phase-II-Data-for-Novel-Neurotrophin-3-Inhibitor-LEVI-04-at-2025-World-Congress-on-Osteoarthritis.html

    GLOBENEWSWIRE
    26 Apr 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search